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A 61-year-old male was referred to our outpatient clinic. Several years before, he had survived five myocardial infarctions before being subjected to coronary bypass surgery. At the time of his first visit to our clinic, he had a non-productive cough and dyspnea with fatigue for 6 weeks. Later, there were small amounts of viscous white sputum which were bloodstained only once. There was no evidence of cardiac failure. He had no history of chronic cough or sputum production despite the fact that he had a 31 pack-years smoking history. There was no weight loss, joint or muscle pain. He did not keep pigeons or other birds, nor did he keep any other domestic animals. He had retired 2n5 years previously. Until then, he was employed in an archive. He had taken isosorbidedinitrate, fenprocoumon and diltiazem for and thus, to a decrease of the serum LDL-cholesterol. To a much lesser extent it lowers the serum VLDLcholesterol and makes the serum HDL-cholesterol level rise. In general, this relatively new compound is well tolerated and only a few, mostly minor, adverse effects have been reported so far. We present a patient who developed interstitial lung disease with pleural effusion most probably as a result of the use of Simvastin.
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Physical examination revealed dyspnea at rest and a respiratory frequency of more than 40 breaths per minute. There was no cyanosis and no lymphadenopathy. Examination of the thorax showed bilateral crackles heard over the lower lungfields. His fingers showed minor signs of clubbing. X-ray examination of the chest at that time showed an interstitial lung disease and pleural effusion that had not been present before.
Laboratory examination showed the following data : ESR 37 mm, haemoglobin 8n1 mmol L −" , haematocrit 40, WBC 12n7i10* L −" , with 70 % neutrophils, 22 % lymphocytes and 1n5 % eosinophils, thrombocyte count 476i10* L −" , serum urea, creatinine and electrolytes were normal. Transaminases were severely elevated, ASAT 740 UL −" (N Fig. 1 The chest X-ray at the moment of referral to our outpatient clinic. It shows a fairly large amount of pleural fluid on the right side with some pleural thickening on the left side and a bilateral interstitial pattern.
15 UL −" ), ALAT 930 UL −" (N 15 UL −" ), LDH 1272 UL −" (N 160 UL −" ), alkaline phosphatase 99 UL −" (N 60 UL −" ), Gamma-GT 53 UL −" (N 28 UL −" ), serum IgE 165 IE ml −" (N 100 IE ml −" ), ACE normal. Autoantibodies (ANF) were not present. The urine analysis showed no abnormalities. Arterial blood sample : pH 7n44, pCO # 3n5 kPa, pO # 8n6 kPa, base excess k4 mmol L −" , SaO # 91 %. Lung function showed a restrictive pattern with a total lung capacity of 67 % of the predicted amount. A mild obstruction was evident (FEV1\VC 70 %) with a diminished carbonmonoxide diffusion (K CO l 36 % predicted).
The chest X-ray showed a fairly large amount of pleural fluid on the right side with some thickening of the pleura on the left side (Fig. 1 ). There was a reticular pattern located peripherally in the right lung and in the left lower lobe. There were no signs of left ventricular failure. The CT scan of the thorax confirmed the large amount of pleural fluid on the right side, and a reticular interstitial pattern in both lungs, more prominent on the right side, with thickened septa. Before any treatment was started, a fiberoptic bronchoscopy was performed. Cell counts in the bronchoalveolar fluid showed 12 % epithelial cells, 34 % eosinophils, 45 % alveolar macrophages, 6 % lymphocytes and only 3 % neutrophils. Bacteriological examination including TBC culture and Ziehl-Neelsen stain of the lavage was negative, as were also the serological tests for Mycoplasma pneumoniae, Chlamydia and respiratory viruses. The cytological examination of the lavage showed reactive bronchial epithelial cells with eosinophilia. The transbronchial biopsies showed predominantly bronchial tissue and only a few alveoli, and were insufficient to diagnose an alveolar disease. The high number of eosinophils in the lavage led to the suspicion of a drug-induced interstitial lung disease [1] . Simvastin was considered the most probable cause, as it had been added to the patient's list of medication only recently. It was decided to discontinue this drug. A few days after the cessation of Simvastin, there was a significant improvement of his liverfunction tests (ASAT 100 UL −" , ALAT 43 UL −" , LDH 345 UL −" ). To further evaluate the effect of discontinuation of Simvastin, a bronchoscopy was repeated a few days later. This time the lavage fluid only showed a slight elevation of 16 % neutrophils, 5 % epithelial cells, 4 % eosinophils, 70 % macrophages and 5 % lymphocytes. We decided to perform a right-sided thoracoscopy. There was darkish brown fluid in the pleural cavity. The parietal pleura showed no abnormalities. The visceral pleura appeared somewhat irregular with anthracosis most prominent in the upper lobes. Biopsies were taken from both the parietal and visceral pleura, and from the left lower lobe of the lung. Cultures showed no microorganisms. Light microscopy of the lungbiopsies showed diffuse fibrosis of the alveolar septa without specific hallmarks. Examination of the pleural fluid revealed non-specific findings. Two weeks after the cessation of Simvastin, the patient's clinical condition had not sufficiently improved and it was decided to prescribe prednisone 40 mg daily. His general condition then improved dramatically within a few days after starting the prednisone. An X-ray of the chest showed only a small amount of pleural fluid and a stationary interstitial pattern. The lung function test showed an improvement of the total lung capacity from 67 to 83 % of the predicted amount. The obstructive component of his lung function remained unchanged as did the carbon monoxide diffusion. We decided to discharge the patient and to taper his prednisone dose. Shortly afterwards, he was admitted to another hospital in shock, highly suspected of having a gastric ulcer and Addison's crise. He died soon after admission. Postmortem examination was not allowed.
Discussion
This patient with an extensive cardiac medical history was admitted to our hospital for analysis of recently developed interstitial lung disease and pleural effusion. Initially, the bronchoalveolar lavage contained an elevated level of eosinophils, which later returned to normal after discontinuation of Simvastin without any additional therapy. An infectious cause for his lung disease was excluded. Auto antibodies were not present and his ESR was only slightly elevated. There were no signs of arthritis or other systemic diseases. Therefore, autoimmune disease was very unlikely. The total IgE level in his serum was elevated. The patient was taking Simvastin for 6 months at admission, during which period he also developed his interstitial lung disease and pleural effusion. Though it does not prove a causal relation, the fact that the number of eosinophils in the bronchoalveolar lavage returned to normal without any additional therapy only a few days after the cessation of Simvastin makes the relationship very likely. Most of the known adverse effects of Simvastin are gastrointestinal. Hepatitis is the most serious complication which may be a reason to discontinue the drug.
A hypersensitivity syndrome has been reported (unpublished data from the manufacturer's product datasheet) with malaise, a lupus-like syndrome, hepatitis and dyspnea, but not with pulmonary or pleural involvement. Pulmonary and pleural disease resulting from the use of Simvastin has not been described before. Although the bronchoalveolar lavage fluid showed a remarkable decrease in the number of eosinophils, the general condition of our patient did not sufficiently improve. Therefore, we decided to prescribe orally administered corticosteroids (40 mg prednisone daily). After 2 days of using prednisone, the patient felt remarkably well and asked to be discharged from the hospital. His lung function test 3 weeks after the cessation of Simvastin and just 2 weeks after starting prednisone therapy showed a major improvement of the restrictive component. The total lung capacity improved from 67 to 83 % of the predicted amount, his TLCO improved from 26 to 35 % of the predicted amount.
To our knowledge, there are no reports of pulmonary or pleural adverse effects from the use of HMG-CoA reductase blockers. However, this patient shows that interstitial lung disease and pleural effusion may result from the use of Simvastin.
